Panulisib

Overview

Panulisib (P7170; AK151761) is an orally active inhibitor of PI3K ( IC 50 = 2.2 nM) and mTOR ( IC 50 = 4.4 nM). Panulisib inhibits ALK1 and DNA-PK , two enzymes that respectively participate in angiogenesis and DNA repair, with IC 50 values of 47 nM and 1.5 nM respectively. Panulisib inhibits cell proliferation and apoptosis . Panulisib can be used for research on breast cancer and non-small cell lung cancer .

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Respiratory Cancer | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Non-Small Cell Lung Cancer | Products > Signaling Pathways > PI3K/Akt/mTOR | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > PI3K | Products > Signaling Pathways > mTOR | Products > Signaling Pathways > Anaplastic lymphoma kinase (ALK) | Products > Signaling Pathways > DNA-PK

Product Information

• Catalog No.: HY-16769
• CAS No.: 1356033-60-7
• Molecular Formula: C27H20F3N9
• Molecular Weight: 527.50
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source